文献速递前列腺癌

TheraP试验:177Lu-PSMA-617与卡巴他赛治疗进展性转移性去势抵抗性前列腺癌的随机2期试验方案

TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
PubMed 文献 · BJU Int · 2019-10-22

TheraP(ANZUP 1603)是一项开放标签、随机、分层、两组、多中心2期试验,旨在比较卡巴他赛化疗与177Lu-PSMA-617治疗经多西他赛治疗后进展的转移性去势抵抗性前列腺癌(mCRPC)男性的活性和安全性。计划入组200例患者,主要终点为PSA缓解,次要终点包括总生存、无进展生存、影像学无进展生存、PSA无进展生存、客观肿瘤缓解、疼痛缓解、疼痛无进展生存、健康相关生活质量及不良事件频率和严重程度。

要点

  • 比较177Lu-PSMA-617与卡巴他赛在经多西他赛治疗的mCRPC中的活性和安全性。
  • 关键入选标准包括PSMA高摄取且无FDG阳性/PSMA阴性不一致病灶。
  • 主要终点为PSA缓解,计划样本量200例,1:1随机。

核心结论

  • 177Lu-PSMA-617可能为mCRPC男性提供一种额外的延长生存的治疗选择。
  • 该试验将首次以随机设计确定177Lu-PSMA-617相较卡巴他赛化疗在进展性mCRPC中的活性和安全性。

研究设计与样本

  • 开放标签、随机、分层、两组、多中心2期试验(ANZUP 1603)。
  • 计划入组200例经多西他赛化疗后PSA升高且PSMA摄取充分的mCRPC男性,1:1随机。

主要发现

  • 原文未报告试验结果,主要终点为PSA缓解。
  • 次要终点包括总生存、无进展生存、影像学无进展生存、PSA无进展生存、客观肿瘤缓解、疼痛缓解、疼痛无进展生存、健康相关生活质量及不良事件。

关键数值与推荐

  • 对照组:卡巴他赛20 mg/m2静脉注射每3周一次,联合泼尼松龙10 mg每日口服,最多10个周期。
  • 试验组:177Lu-PSMA-617 8.5 GBq静脉注射每6周一次,每周期递减0.5 GBq,最多6个周期。
  • 关键入选标准:既往多西他赛化疗、PSA升高、中心审查的68Ga-PSMA-11和FDG-PET/CT显示PSMA摄取充分且无FDG高摄取/PSMA阴性不一致病灶。

临床怎么用

  • 对于经多西他赛治疗后进展的mCRPC患者,可考虑筛选PSMA高摄取且无FDG不一致病灶者入组该随机试验。
  • 治疗选择需基于PSMA和FDG-PET/CT评估结果。

局限性

  • 本文为试验方案,尚未报告结果。
  • 研究为2期试验,样本量计划200例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in men with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel treatment. PATIENTS AND METHODS: The TheraP trial (ANZUP 1603) is an open-label, randomized, stratified, two-arm multicentre phase 2 trial comparing the activity and safety of cabazitaxel chemotherapy vs 177 Lu-PSMA-617 therapy in the treatment of men with mCRPC. Key eligibility criteria include prior docetaxel chemotherapy, rising prostate-specific antigen (PSA) level, sufficient PSMA avidity, as defined by centrally reviewed 68 Ga-PSMA-11 and fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) with no discordant FDG-avid PSMA-negative sites of disease. Patients in the control group receive standard treatment with cabazitaxel (20 mg/m2 ) i.v. every 3 weeks with prednisolone 10 mg daily orally, for a maximum of 10 cycles. Patients in the experimental group receive 177 Lu-PSMA-617 (8.5 GBq decreasing by 0.5 GBq per cycle) i.v. every 6 weeks, for up to a maximum of six cycles. In the event of an exceptional response as defined on centrally reviewed post-therapy single-photon emission CT imaging, treatment will be suspended but can recommence on progression. The trial aims to include 200 patients who will be centrally randomized to one of the two treatment groups, in a 1:1 ratio. The primary endpoint is PSA response. Secondary endpoints are overall survival, progression-free survival (PFS), radiographic PFS, PSA PFS, objective tumour response, pain response, pain PFS, health-related quality of life, and frequency and severity of adverse events. The treatment and outcomes of patients excluded on the basis of low PSMA avidity or discordant FDG-avid disease on screening 68 Ga-PSMA-11 and Fluorine-18 (18 F)-FDG-PET/CT scan will also be assessed. Enrolment in the study commenced on 29 January 2018. RESULTS AND CONCLUSIONS: 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC. The results of this trial will determine, for the first time in a randomized design, the activity and safety of 177 Lu-PSMA-617, as compared with cabazitaxel chemotherapy in men with progressive mCRPC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hofman MS, Emmett L, Violet J, et al. TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019. PMID: 31638341. doi:10.1111/bju.14876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。